We listened to healthcare professionals like you to develop resources that will help you transition your patients to immune globulin intravenous (IGIV)

MMN Rx Form

Designed to facilitate GAMMAGARD LIQUID prescriptions and used for benefits verification and other insurance coverage support.

For information, call 1-888-229-8379

Coverage Assistance

We've enhanced our services to help you secure health insurance coverage for your MMN patients.

  • Billing resources
  • Benefits verification
  • Prior authorization resources
  • Appeal resources

For information, call 1-888-229-8379

Shire offers support to patients with MMN by providing educational resources, practical information, and valuable connections for them and their families.

Useful Tools and clear information on managing life with MMN.

Connects patients with nurses with IVIG treatment experience who can offer assistance and answer questions about GAMMAGARD LIQUID treatment

Provide tools and resources for your patients that complement the education and support you and your staff provide

Encourage your patients to enroll in MyIgSource by calling 1-855-250-5111 or on GAMMAGARD.com

MyIgSource is open to all patients regardless of treatment.

These helpful resources are available for you to download right now.

MyIgSource Summary

An overview of what patients can expect from MyIgSource for those who are currently on or starting IVIG treatment for MMN.

Key program benefits include:

  • Disease information
  • Live support for patients
  • Educational resources

MMN Overview

An overview of MMN, including information about diagnosis, misdiagnosis, and treatment.

 

Electrodiagnostic Testing Summary

Provides an overview of electromyography and nerve conduction studies. These studies are one of several tools that healthcare providers may use to identify the causes and severity of nerve damage.

Encourage your patients to enroll in MyIgSource by calling 1-855-250-5111 or on GAMMAGARD.com

MyIgSource is open to all patients regardless of treatment.

Once enrolled, your patient will receive a MyIgSource Support Welcome Kit and IVIG Infusion Log. In addition, patients will be connected with a nurse advocate.

Welcome Kit

Provides people who are newly diagnosed with MMN (and being treated with IVIG) with detailed information about the disease and treatment.

This kit includes:

  • An introduction to MMN
  • Background information about MMN and how treatment can affect your daily life
  • The basics of GAMMAGARD LIQUID

IVIG Infusion Log

A tool to help patients keep track of their treatments and communicate how their infusions are going with your doctor.

This log can help you:

  • Keep a consistent infusion schedule
  • Manage their treatment schedule together with you, the healthcare professional

Nurse Advocate

Once enrolled in MyIgSource, patients will be contacted by and have ongoing access to a nurse advocate who is experienced with IVIG infusions.

The key benefits are:

  • Live support for patients
  • Ongoing support to help patients enhance their overall healthcare experience

Encourage your patients to enroll in MyIgSource by calling 1-855-250-5111 or on GAMMAGARD.com

MyIgSource is open to all patients regardless of treatment.

GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE

  • Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.
  • For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
  • GAMMAGARD LIQUID is contraindicated in patients who have a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of human immune globulin. GAMMAGARD LIQUID is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.
  • HYPERSENSITIVITY: IgA deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. In case of hypersensitivity, discontinue GAMMAGARD LIQUID infusion immediately and institute appropriate treatment.
  • RENAL DYSFUNCTION/FAILURE: Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.
  • Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving GAMMAGARD LIQUID.
  • THROMBOSIS: Thrombosis may occur following treatment with immune globulin products, including GAMMAGARD LIQUID. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
  • Aseptic Meningitis Syndrome (AMS) may occur with IGIV treatment, and has been reported with intravenous (IV) use of GAMMAGARD LIQUID. AMS may occur more frequently with high dose (2 g/kg) IGIV treatment and/or rapid infusion of IGIV.
  • Hemolytic anemia can develop subsequent to GAMMAGARD LIQUID treatment due to enhanced RBC sequestration. Risk factors may include: high doses (e.g., ≥2 g/kg cumulative dose), non-O blood group, and underlying inflammation. Monitor patients for clinical signs and symptoms of hemolysis and delayed hemolytic anemia.
  • Transfusion-Related Acute Lung Injury (TRALI): Non-cardiogenic pulmonary edema has been reported in patients following treatment with IGIV products, including GAMMAGARD LIQUID. Monitor patients for pulmonary adverse reactions.
  • GAMMAGARD LIQUID is made from human blood. It may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. No confirmed cases of viral transmission or vCJD have been associated with GAMMAGARD LIQUID.
  • Passive transfer of antibodies may transiently impair the immune responses to live attenuated virus vaccines such as mumps, rubella, varicella, and measles. This passive transfer may also yield false positive serological testing results, with the potential for misleading interpretation.

The serious adverse reactions in the MMN (IV administration) clinical trial were pulmonary embolism and blurred vision. The most common adverse reactions observed in ≥ 5% of patients in the clinical trials were:

MMN (IV administration): Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity.

Please see the accompanying full Prescribing Information, including Boxed Warning.

To report suspected adverse reactions, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report suspected adverse reactions, contact Shire Drug Safety at 1-800-999-1785 or .

If you have a medical or clinical question regarding the use of GAMMAGARD LIQUID, please contact Shire Medical Information at 1-866-424-6724 or

Insurance Support

Get help with expedited benefits verification and other insurance coverage resources for GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%.

CALL

1-888-229-8379